CML-BP

AcronymDefinition
CML-BPChronic Myelogenous Leukemia in Blast Phase
References in periodicals archive ?
Troxatyl's activity in patients with CML blastic phase is truly exciting and, based on data available to date, may have a major role in the treatment of CML-BP patients.
To further explore the potential of Troxatyl therapy in CML-BP, BioChem will be initiating both multicentre open-label, single agent and randomized studies in chemotherapy-naive patients, but including patients who have failed the investigational tyrosine kinase inhibitor, STI-571.
Such forward-looking statements include, without limitation, the expectation that TroxatylTM may have a major role in the treatment of CML-BP patients.